TLDR: Veeda Lifesciences has announced a strategic investment in Mango Sciences, a healthcare AI and data company, to integrate advanced AI capabilities into its clinical trial services. This collaboration aims to significantly enhance the speed, efficiency, and quality of clinical trials, particularly in oncology drug development, by leveraging AI for improved patient identification, diverse recruitment, and streamlined operations.
AHMEDABAD, India – July 8, 2025 – Veeda Lifesciences, a prominent global contract research organization (CRO), has officially announced a significant investment in Mango Sciences, a Boston-based healthcare AI and data company. This strategic partnership is set to revolutionize clinical trial services by integrating cutting-edge artificial intelligence (AI) innovation, with a primary focus on enhancing the speed, efficiency, and overall quality of clinical trials across Veeda’s expanding global network.
The collaboration aims to enable more diverse and efficient patient recruitment, ensuring globally representative patient selection. A cornerstone of this initiative is the deployment of Mango Sciences’ proprietary AI-powered Querent™ platform. This technology will empower Veeda to automate patient identification with remarkable precision and extend its reach across Europe, streamlining critical processes within clinical research operations.
Dr. Mahesh Bhalgat, Group CEO and Managing Director of Veeda Clinical Research Limited, emphasized the transformative potential of this alliance. “Our partnership will transform Veeda into an AI-driven oncology drug development organization, meeting the growing demand for diversity in clinical trials, which is in line with the expectations of regulators and pharmaceutical companies,” stated Dr. Bhalgat. He further added, “We will be one of only a few CROs focused in Oncology with access to this proprietary technology.”
This partnership aligns with Veeda’s broader objectives of investing in technology modernization and digital transformation to enhance operational efficiency and quality assurance. By leveraging the Querent™ platform, Veeda expects to improve data management capabilities and ensure higher quality standards through broader representation of non-Caucasian populations in trials. This integration is anticipated to enhance clinical trial efficiency through advanced data analytics, leading to improved patient matching, optimized trial design, and more effective monitoring, ultimately reducing costs and timelines.
Dr. Mohit Misra, Founder & CEO of Mango Sciences, highlighted the technological advancements being integrated. “We are integrating Large Language Models (LLMs) and Generative-AI into Querent™ to drive operational efficiencies and improve real-world evidence, ultimately identifying the right drug for the right patient,” Dr. Misra explained.
Also Read:
- Indian Pharma Global Capability Centers Revolutionize Drug Development with AI Integration
- LogicFlo Secures $2.7M to Revolutionize Life Sciences Workflows with Compliant AI Agents
Veeda Lifesciences has been actively strengthening its position as a tech-enabled, AI-driven CRO through strategic investments and prior acquisitions, including Health Data Specialists (Heads). These moves have provided Veeda with access to valuable oncology cohorts in India and Europe, along with exclusive access to eligible patient pools, reinforcing its competitive edge in the CRO sector and its commitment to delivering high-quality services to pharmaceutical and biopharmaceutical clients worldwide.
